2023³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦21Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2023-05-19
±³À°ÀÏÀÚ : 2023-05-19
±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ¼¿ï
±³À°ÁÖÁ¦ : 2023³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦21Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ±è¿¹Áö
¿¬¶ôó : 070-4367-2707
À̸ÞÀÏ : meetings@ksmo.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í "(ȸ¿ø) -Á¤È¸¿ø 40,000 60,000 -ÁØȸ¿ø 30,000 50,000 (ºñȸ¿ø) -±³¼ö, Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø 50,000 70,000 -ÀüÀÓÀÇ, Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý 30,000 50,000 -¾÷ü Âü°¡ 60,000 80,000"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 09:00~09:40 Novel approaches to tailoring therapy for typical and atypical EGFR mutations John Heymach(MDACC)
Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 09:40~09:50 Discussion ( )
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 10:00~10:20 Case sharing KOSMOS molecular tumor board ¹Ú¼÷·Ã(¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 10:20~10:40 Liquid biopsy-guided basket trial -are we ready? : Overview ±èÅ¿ë(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 10:40~11:00 Liquid biopsy-guided basket trial -are we ready? : Technical aspects and limitations °ø¼±¿µ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 11:00~11:20 An updated consensus on the use of NGS in patients with advanced cancer : A joint report KSMO and KSP ±è¹Ì¼Ò(¼¿ï´ëº´¿ø Á¾¾ç³»°ú)
Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 11:20~11:30 Discussion ( )
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 11:30~12:10 Landmark Clinical Trials Guiding the Current Clinical Practice in Adjuvant Treatment for Resectable Gastric Cancer °¿ø±â(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 12:20~13:00 Pembrolizumab for the treatment of thoracic malignancies, Lung, Head and Neck, and Esophageal cancer È«¹ÎÈñ(¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 13:00~13:20 Ç×¾ÏÁ¦ °¡Ä¡Æò°¡ ±âÁØ, ¿Ü±¹ Æò°¡ ±âÁØ°ú Çѱ¹(Value framework (ASCO), MCBS (ESMO), Korean) °ÁøÇü(Ä«Å縯´ëÇб³¼º¸ðº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 13:20~13:40 Ç×¾ÏÁ¦ °¡Ä¡ Æò°¡ ±âÁØ, ½Å¾à µîÀç °úÁ¤¿¡¼ÀÇ Àû¿ë, »ç·Ê ¹× ¹®Á¦Á¡ ±è±¹Èñ(½ÉÆò¿ø ¾àÁ¦°ü¸®½Ç, ½Å¾àµîÀçºÎ)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 13:40~14:00 Çã°¡ ÃÊ°ú ÀǾàÇ°ÀÇ ºñ±Þ¿© »ç¿ë, »çÀü ½ÅûÀÇ ±Ù°Å¿Í ÀÓ»ó¿¡¼ÀÇ ÇÑ°è ÀÌÀç·Ã(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 14:00~14:20 Çã°¡ ÃÊ°ú ÀǾàÇ°ÀÇ ºñ±Þ¿© »ç¿ë¿¡ ´ëÇÑ ¾ÏÁúȯ ½ÉÀÇÀ§¿øȸÀÇ Æò°¡ ±âÁØ°ú °³¼± ¹æ¾È ÀÓÈ£¿µ(¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø, ¾ÏÁúȯ½ÉÀÇÀ§¿øȸÀå)
Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 11:20~11:30 Discussion ( )
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 14:40~15:00 Predicting response to immunotherapy using single cell genomics ±èÇý·Ã(¿¬¼¼¼¼ºê¶õ½º)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 15:00~15:20 AI-based biomarkers predicting clinical outcomes of immuno-oncology agents ¿ÁÂù¿µ(·ç´Ö)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 15:20~15:40 Predicting the efficacy and toxicity of immunotherapy using blood samples patients ÀüÈ«Àç(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 15:40~16:00 Maximizing the therapeutic efficacy of immunotherapy through T cell characterization analysis ½ÅÀÇö(Ä«À̽ºÆ®)
Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 16:00~16:10 Discussion ( )
±³À°½Ã°£ 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 16:10~16:50 How to build a international collaboration: experience of ESMO Asia Ravindran Kanesvaran(Deputy Chair and Senior Consultant , Division of Medical Oncology, National Cancer Centre Singapore)
Åä·Ð 05¿ù 19ÀÏ Å©¸®½ºÅ»º¼·ë 16:50~17:00 Discussion ( )